114 related articles for article (PubMed ID: 2785095)
21. [The anti-tumor efficacy of lymphokine-activated killer (LAK) cells induced in vitro from peripheral blood lymphocytes of patients with malignant glioma].
Shimizu K; Miyao Y; Okamoto Y; Matsui Y; Ushio Y; Tsuda N; Hayakawa T; Ishida N; Mogami H
No To Shinkei; 1986 Mar; 38(3):265-71. PubMed ID: 3085695
[TBL] [Abstract][Full Text] [Related]
22. Lymphokine-activated killer-cell function of lymphocytes from peripheral blood, regional lymph nodes and tumor tissues of patients with oral cancer.
Tatake RJ; Krishnan N; Rao RS; Fakih AR; Gangal SG
Int J Cancer; 1989 Apr; 43(4):560-6. PubMed ID: 2522911
[TBL] [Abstract][Full Text] [Related]
23. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
Colquhoun SD; Economou JS; Shau H; Golub SH
J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
[TBL] [Abstract][Full Text] [Related]
24. Normal development of lymphokine activated killing (LAK) in peripheral blood lymphocytes from hyperprolactinemic patients.
Matera L; Ciccarelli E; Muccioli G; Cesano A; Grottoli S; Oberholtzer E; Camanni F
Int J Immunopharmacol; 1992 Oct; 14(7):1235-40. PubMed ID: 1452408
[TBL] [Abstract][Full Text] [Related]
25. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
26. Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.
Grimm EA; Ramsey KM; Mazumder A; Wilson DJ; Djeu JY; Rosenberg SA
J Exp Med; 1983 Mar; 157(3):884-97. PubMed ID: 6601174
[TBL] [Abstract][Full Text] [Related]
27. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE
Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186
[TBL] [Abstract][Full Text] [Related]
28. [Experimental studies on induction of various lymphokine-activated killer cells using recombinant interleukin 2].
Takao H; Saji S; Sugiyama Y; Tachibana S; Goshima H; Morita T; Sakata K
Nihon Geka Gakkai Zasshi; 1988 May; 89(5):646-54. PubMed ID: 3261830
[TBL] [Abstract][Full Text] [Related]
29. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
[TBL] [Abstract][Full Text] [Related]
30. Characteristics of interleukin-6-enhanced lymphokine-activated killer cell function.
Iho S; Shau HY; Golub SH
Cell Immunol; 1991 Jun; 135(1):66-77. PubMed ID: 2018984
[TBL] [Abstract][Full Text] [Related]
31. Lymphokine-activated effector cells: modulation of activity by cytokines.
Mehta S; Flanagan P; Blackinton D; Wanebo H
Lymphokine Cytokine Res; 1992 Apr; 11(2):73-7. PubMed ID: 1581419
[TBL] [Abstract][Full Text] [Related]
32. The human lymphokine-activated killer cell system. V. Purified recombinant interleukin 2 activates cytotoxic lymphocytes which lyse both natural killer-resistant autologous and allogeneic tumors and trinitrophenyl-modified autologous peripheral blood lymphocytes.
Grimm EA; Wilson DJ
Cell Immunol; 1985 Sep; 94(2):568-78. PubMed ID: 3928175
[TBL] [Abstract][Full Text] [Related]
33. Functional heterogeneity of Leu 19"bright"+ and Leu 19"dim"+ lymphokine-activated killer cells.
Ellis TM; Fisher RI
J Immunol; 1989 Apr; 142(8):2949-54. PubMed ID: 2467946
[TBL] [Abstract][Full Text] [Related]
34. Induction of lymphokine-activated killer activities in peripheral blood lymphocytes and regional lymph node lymphocytes against PC-9 cultured adenocarcinoma and autologous pulmonary adenocarcinoma cells.
Morikawa Y; Watanabe S; Kodama T
Jpn J Clin Oncol; 1987 Jun; 17(2):129-39. PubMed ID: 3497285
[TBL] [Abstract][Full Text] [Related]
35. Different immune functions of peripheral blood, regional lymph node, and tumor infiltrating lymphocytes in lung cancer patients.
Nakamura H; Ishiguro K; Mori T
Cancer; 1988 Dec; 62(12):2489-97. PubMed ID: 3142676
[TBL] [Abstract][Full Text] [Related]
36. Differential effects of recombinant interferons alpha, beta, and gamma on induction of human lymphokine (IL-2)-activated killer activity.
Sone S; Utsugi T; Nii A; Ogura T
J Natl Cancer Inst; 1988 May; 80(6):425-31. PubMed ID: 3130488
[TBL] [Abstract][Full Text] [Related]
37. Interleukin 2 induces human acute lymphocytic leukemia cells to manifest lymphokine-activated-killer (LAK) cytotoxicity.
Kaufmann Y; Levanon M; Davidsohn J; Ramot B
J Immunol; 1987 Aug; 139(3):977-82. PubMed ID: 3496395
[TBL] [Abstract][Full Text] [Related]
38. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
Kalland T; Belfrage H; Bhiladvala P; Hedlund G
J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
[TBL] [Abstract][Full Text] [Related]
39. Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer.
Rayner AA; Grimm EA; Lotze MT; Chu EW; Rosenberg SA
Cancer; 1985 Mar; 55(6):1327-33. PubMed ID: 3871657
[TBL] [Abstract][Full Text] [Related]
40. Peripheral blood lymphocytes from thermal injury patients are defective in their ability to generate lymphokine-activated killer (LAK) cell activity.
Klimpel GR; Herndon DH; Stein MD
J Clin Immunol; 1988 Jan; 8(1):14-22. PubMed ID: 2966807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
